EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024 PRESS RELEASE EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024 Paris, France, 9 December 2024 – EnnoDC, a clinical-stage biotech...

EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy PRESS RELEASE EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy Versatile new technology featuring an...

Beroni Group Signs MoU with tella, Inc to Collaborate in Immunotherapy for Cancer Treatment NEW YORK and SYDNEY, Australia, May 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today...

Outlook on the Cell Therapy Biomanufacturing Global Market to 2025 - by Product Type, Application and Region Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Biomanufacturing: Global Markets" report has been added to ResearchAndMarkets.com's offering. This research report presents an in-depth...